Views Expressed Disclaimer: You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. 

When investors think about artificial intelligence opportunities, the spotlight almost always falls on Silicon Valley giants such as Nvidia, Microsoft, Alphabet, and Meta. London rarely enters that conversation. The FTSE 100 is better known for oil majors, pharmaceutical leaders, and dividend-paying banks than for cutting-edge technology. Pure technology companies represent only a small fraction of the UK’s flagship index.

However, a closer look reveals a far more compelling story. Across the FTSE 100 and FTSE 250, several companies are quietly embedding artificial intelligence into their core businesses, supplying critical infrastructure for the global AI expansion, or providing investors with diversified exposure to one of the most transformative megatrends of the century. With the global AI market projected to exceed $3 trillion by 2033, London-listed firms are increasingly positioned to capture meaningful long-term growth.

Here are some of the most attractive FTSE AI stocks investors should be watching right now.

Source: Kalkine Group

Rolls-Royce: A Hidden AI Infrastructure Leader

Rolls-Royce might not immediately appear to be an AI stock, but the engineering powerhouse is rapidly becoming one of the UK market’s most interesting artificial intelligence beneficiaries.

The opportunity comes from two major areas. First, its Power Systems division produces backup generators and energy solutions that support data centres — the backbone of AI computing. As hyperscale companies such as Microsoft, Amazon, and Google invest billions into AI infrastructure, demand for reliable power solutions continues to surge. Rolls-Royce has already secured contracts across the AI ecosystem, positioning itself as an essential but often overlooked supplier.

Second, the company is integrating AI directly into its operations. Smart sensors embedded in jet engines enable predictive maintenance, improving efficiency while reducing downtime and costs. Partnerships with technology firms are also advancing autonomous maritime navigation and AI-driven engineering design.

Following a major turnaround under CEO Tufan Erginbilgic, Rolls-Royce has restored profitability and strengthened its balance sheet. While the valuation is no longer cheap, the combination of aerospace recovery, defence spending growth, and AI-related revenue streams creates a powerful multi-year investment case.

Halma: Data Centre Growth Meets Defensive Quality

Halma has built a reputation as one of the FTSE 100’s most consistent compounders. The company acquires niche technology businesses focused on safety, health, and environmental solutions — sectors often supported by regulation, which provides strong recurring demand.

More recently, Halma has emerged as an indirect beneficiary of the AI boom. Its subsidiary Avo Photonics supplies optical components used inside data centres, which are critical for high-performance computing and AI workloads. Rising demand from hyperscale customers has already contributed to strong revenue growth and improved profitability.

Although Halma trades at a premium valuation compared with the broader market, investors often pay higher multiples for businesses with durable competitive advantages, predictable earnings, and long-term structural growth exposure.

AstraZeneca: Artificial Intelligence Transforming Drug Discovery

Artificial intelligence is reshaping pharmaceutical research, and AstraZeneca is at the forefront of this shift. The company is applying machine learning to accelerate drug discovery, particularly in oncology, where identifying viable treatments requires analysing massive biological datasets.

Strategic acquisitions and technology partnerships are strengthening AstraZeneca’s AI capabilities, potentially shortening development timelines and improving success rates. With one of the strongest pipelines in global pharmaceuticals, AI integration could further enhance long-term growth.

The stock commands a premium valuation, reflecting both its market leadership and consistent performance, but AI-driven innovation adds another layer of future upside that investors may still underestimate.

Experian: AI Strengthening a Powerful Data Moat

Experian’s vast global database and analytics capabilities make it naturally aligned with artificial intelligence adoption. The company uses AI to enhance credit scoring, fraud detection, and automated financial decision-making tools across consumer and enterprise markets.

Despite strong fundamentals — including solid revenue growth and high returns on equity — the share price has faced pressure due to investor concerns about AI disruption. However, rather than threatening Experian’s business model, AI is likely to reinforce its competitive advantage by improving accuracy and efficiency.

For long-term investors, the disconnect between market sentiment and operational performance may represent an attractive opportunity.

Oxford Nanopore Technologies: AI and Genomics Converge

Oxford Nanopore Technologies offers one of the most innovative AI-adjacent investment stories in the UK. The company develops advanced DNA and RNA sequencing technology that uses artificial intelligence to improve speed, accuracy, and scalability.

Recent trading updates show strong revenue growth across multiple segments, including clinical and biopharma markets. Importantly, the company is approaching a potential profitability inflection point, with sufficient cash reserves to support future expansion.

Although the stock remains volatile and carries higher risk than established FTSE giants, it sits at the intersection of two transformative industries: genomics and artificial intelligence.

Kainos Group: A Pure-Play AI Adoption Story

Kainos provides digital transformation and AI consulting services, particularly within the UK public sector. The company has completed hundreds of AI-related projects for organisations including government departments and healthcare systems.

Its expertise in regulated environments, combined with strong earnings growth forecasts, makes Kainos one of the more direct ways investors can gain exposure to enterprise AI adoption trends in the UK market.

Allianz Technology Trust: Diversified Global AI Exposure

Investors who prefer diversification over individual stock selection may consider Allianz Technology Trust. The investment trust provides exposure to leading global technology and AI companies through a single London-listed vehicle.

With a strong long-term performance track record and occasional discounts to net asset value, the trust offers a practical approach for investors seeking broad participation in the global AI revolution without concentrating risk in one company.

Why the FTSE Offers a Different AI Opportunity

London will never rival Nasdaq as a hub for pure-play AI companies. Several high-profile UK technology firms have chosen US listings or private ownership instead. However, the FTSE offers something different — established, profitable businesses integrating artificial intelligence into industries they already dominate.

Rolls-Royce is enabling AI infrastructure. Halma is supplying critical components. AstraZeneca is transforming drug discovery. Experian is embedding AI into financial systems. These are not speculative startups but mature companies with proven revenue streams and global market positions.

For investors seeking exposure to artificial intelligence without paying Silicon Valley valuations, the FTSE market deserves far greater attention. The UK’s AI investment opportunity may be quieter — but it could also prove more durable over the long term.

*Disclaimer: This article is for informational purposes only and does not constitute financial advice. The value of investments can fall as well as rise, and you may receive back less than you invest. Past performance is not a reliable indicator of future results. Always conduct your own research or consult a qualified financial adviser before making investment decisions.*